Incyte Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Incyte ha aumentado sus beneficios a una tasa media anual de 25.4%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.8% anual. Los ingresos han ido creciendo a una tasa media de 13.7% al año. La rentabilidad financiera de Incyte es de 11.5%, y sus márgenes netos son de 16.2%.

Información clave

25.1%

Tasa de crecimiento de los beneficios

24.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	12.9%
Tasa de crecimiento de los ingresos	13.2%
Rentabilidad financiera	13.8%
Margen neto	19.8%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Incyte. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BMV:INCY * Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	3,768	745	1,143	6
31 Dec 23	3,696	598	1,159	0
30 Sep 23	3,609	425	1,138	31
30 Jun 23	3,513	366	1,136	31
31 Mar 23	3,470	324	1,105	31
31 Dec 22	3,395	341	999	0
30 Sep 22	3,331	876	954	0
30 Jun 22	3,320	945	879	0
31 Mar 22	3,115	933	796	0
31 Dec 21	2,986	949	741	0
30 Sep 21	2,913	535	682	0
30 Jun 21	2,721	338	612	0
31 Mar 21	2,703	478	561	0
31 Dec 20	2,667	-296	518	0
30 Sep 20	2,457	-335	487	0
30 Jun 20	2,388	-191	469	0
31 Mar 20	2,229	-376	457	0
31 Dec 19	2,159	447	469	0
30 Sep 19	2,108	405	441	0
30 Jun 19	2,006	306	435	0
31 Mar 19	1,997	253	437	0
31 Dec 18	1,882	109	435	0
30 Sep 18	1,798	-109	424	0
30 Jun 18	1,729	-102	419	0
31 Mar 18	1,534	-167	401	0
31 Dec 17	1,536	-313	367	0
30 Sep 17	1,419	-155	363	0
30 Jun 17	1,306	-154	348	0
31 Mar 17	1,226	-107	324	0
31 Dec 16	1,106	104	302	0
30 Sep 16	1,023	151	260	0
30 Jun 16	941	74	231	0
31 Mar 16	858	49	216	0
31 Dec 15	754	7	197	0
30 Sep 15	634	-86	193	0
30 Jun 15	644	13	184	0
31 Mar 15	581	-33	174	0
31 Dec 14	511	-48	166	0
30 Sep 14	485	-54	155	0
30 Jun 14	372	-136	142	0
31 Mar 14	374	-101	125	0
31 Dec 13	355	-83	110	0
30 Sep 13	372	-21	96	0
30 Jun 13	347	-21	90	0

Ingresos de calidad: INCY * tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (16.2%) de INCY * son superiores a los del año pasado (10%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lINCY * han crecido significativamente en un 25.4% al año.

Acelerando crecimiento: El crecimiento de los beneficios de INCY * en el último año (75.4%) supera su media de 5 años (25.4% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de INCY * en el último año (75.4%) superó al de la industria Biotechs -2.6%.

Incyte Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Recent updates

Incyte Corporation, Annual General Meeting, Jun 12, 2024

Incyte Corporation Maintains Earnings Guidance for 2024

Incyte Corporation (NasdaqGS:INCY) entered into a definitive agreement to acquire Escient Pharmaceuticals, Inc. from a group of shareholders for $750 million.

Incyte Corporation to Report Q1, 2024 Results on Apr 30, 2024

Incyte Announces New Results from A Phase 2 Study Evaluating the Efficacy and Safety of Twice-Daily Ruxolitinib Cream 1.5% (Opzelura®) in Adult Patients with Hurley Stage 1 or 2 (Mild-To-Moderate) Hidradenitis Suppurativa (HS)

Full year 2023 earnings released: EPS: US$2.67 (vs US$1.53 in FY 2022)

Incyte Corporation Provides Earnings Guidance for 2024

New minor risk - Profit margin trend

Incyte Corporation to Report Q4, 2023 Results on Feb 13, 2024

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Incyte Corporation Provides Earning Guidance for the Full Year 2023

Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo

Incyte Corporation to Report Q3, 2023 Results on Oct 31, 2023

Incyte Corporation Announces Executive Changes, Effective November 1, 2023

Incyte Corporation Revises Earnings Guidance for the Year 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Incyte Corporation to Report Q2, 2023 Final Results on Aug 01, 2023

Incyte Corporation Appoints Pablo J. Cagnoni, M.D. as President and Head of Research & Development, Effective June 5, 2023

Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa

Incyte Corporation Provides Earnings Guidance for the Year 2023

Incyte Corporation to Report Q4, 2022 Results on Feb 07, 2023

Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Incyte Corporation Announces Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte Corporation to Report Q3, 2022 Results on Nov 01, 2022

Incyte Announces the Appointment of Susanne Schaffert as New Member of Its Board of Directors

Incyte Corporation (NasdaqGS:INCY) entered into an agreement to acquire Villaris Therapeutics, Inc. from Medicxi Ventures (UK) LLP and others for $1.4 billion.

Incyte Corporation Announces FDA Approval Of Pemazyre® (Pemigatinib) As The First And Only Targeted Treatment For Myeloid/Lymphoid Neoplasms (MLNs) With FGFR1 Rearrangement

Incyte Corporation Reaffirms Revenue Guidance for the Full Year 2022

Incyte Corporation Announces U.S. FDA Approval of Opzelura Cream for the Treatment of Vitiligo

Incyte Corporation to Report Q2, 2022 Results on Aug 02, 2022

FDA Approves Eli Lilly and Company and Incyte's OLUMIANT® (baricitinib) as First and Only Systemic Medicine for Adults with Severe Alopecia Areata

Chmp Recommends Approval of Eli Lilly and Company and Incyte's Olumiant® (Baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (Aa)

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

Incyte Announces European Commission Approval of Jakavi (Ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease

Incyte Corporation, Annual General Meeting, Jun 15, 2022

Incyte Announces Positive Committee for Medicinal Products Opinion for Capmatinib (Tabrecta®) for the Treatment of Metex14 Advanced Non-Small Cell Lung Cancer

Incyte Corporation to Report Q1, 2022 Results on May 03, 2022

Incyte Corporation Provides Revenue Guidance for the Full Year 2022

Incyte Announces Acceptance and Priority Review of SNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: EPS US$0.82 (vs US$0.069 loss in 3Q 2020)

Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million.

Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

Incyte Announces Health Canada Conditional Approval of Pemazyre® (pemigatinib) as First Targeted Treatment for Adults

Calithera Biosciences, Inc. Enters into A Settlement Agreement and Release with Incyte Corporation

Incyte Announces Health Canada Approval of Minjuvi® in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Eli Lilly and Company and Incyte Announce Results from an Additional Cohort of 101 Adult Patients from the COV-Barrier Trial

Incyte Announces Positive Phase 3 REACH3 Study Data Published in NEJM for Ruxolitinib (Jakafi) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis

Incyte Corporation Announces U.S. Food and Drug Administration Extends sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease

Incyte and MorphoSys US, Inc. Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Incyte Corporation Announces Positive Primary Analysis from the Phase 2 Optic Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (Cp-Cml) to Be Presented At the 2021 Asco Annual Meeting

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

Incyte Corporation Provides Revenue Guidance for the Full Year 2021

Incyte Announces Results from the Phase 3 DEVENT Study Evaluating Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) on Mechanical Ventilation

Eli Lilly and Company and Incyte Announce Top-Line Results from BRAVE-AA2

Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as Treatment for Patients with Squamous Cell Anal Carcinoma

Chairman recently bought Mex$21m worth of stock

Incyte Announces Acceptance and Priority Review of sNDA for Jakafi® (Ruxolitinib) as A Treatment for Patients with Chronic Graft-Versus-Host Disease

Incyte Announces Acceptance and Priority Review of NDA for Ruxolitinib Cream for Atopic Dermatitis

Revenue beats expectations

Full year 2020 earnings released: US$1.36 loss per share (vs US$2.08 profit in FY 2019)

Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement

Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as A Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (Scac)

Desglose de ingresos y gastos
Beta